Trial
NCT05537402
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Genentech, Inc.
Condition
Hepatocellular Carcinoma
Intervention
Atezolizumab and bevacizumab
Why stopped
The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18